(3,3-Dimethyl-2-oxobutyl) 2,6-dichlorobenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,3-Dimethyl-2-oxobutyl) 2,6-dichlorobenzoate
• 化学式: C₁₃H₁₄Cl₂O₃
• 分子量: 289.15
• InChiKey: UXLTZWOUJGBPRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Functionalized peptides as antiviral agents
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US11358953B2

  公开（公告）日：2022-06-14

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了式（I）化合物及其药学上可接受的盐类： 其可抑制冠状病毒的复制活性。本发明进一步涉及包含式（I）化合物或其药学上可接受的片剂的药物组合物，以及治疗或预防有需要的受试者感染冠状病毒的方法，包括向受试者施用治疗有效量的式（I）化合物或其药学上可接受的盐。
• FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20220033383A1

  公开（公告）日：2022-02-03

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.